Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Achilles Therapeutics plc - American Depositary Shares (NQ: ACHL )

1.120 -0.040 (-3.45%)
Streaming Delayed Price Updated: 10:55 AM EST, Jan 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Achilles Therapeutics plc - American Depositary Shares

< Previous 1 2 3 Next >
Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts
Achilles Therapeutics announces a $12M deal with AstraZeneca for TRACERx data and plans job cuts following its strategic review. 
Via Benzinga
Achilles Therapeutics Shares Are Trading Higher: What You Need To Know
Shares of Achilles Therapeutics plc (NASDAQ: ACHL) are surging following a major strategic announcement from the company. The biotechnology firm revealed plans to discontinue its TIL-based cNeT program... 
Via Benzinga
ACHL Stock Earnings: Achilles Therapeutics Meets EPS for Q2 2024
ACHL stock results show that Achilles Therapeutics met analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
From Achilles Therapeutics PLC
Via GlobeNewswire
ACHL Stock Earnings: Achilles Therapeutics Beats EPS for Q1 2024
ACHL stock results show that Achilles Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Achilles Therapeutics: Q1 Earnings Insights
Via Benzinga
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88.... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 0.49% to 39,319.03 while the NASDAQ rose 1% to 16,4340. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%... 
Via Benzinga
ACHL Stock Earnings: Achilles Therapeutics Misses EPS for Q4 2023
ACHL stock results show that Achilles Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Thursday morning! 
Via InvestorPlace
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies 
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via Investor Brand Network
Exposures Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics to Present at Upcoming Conferences
From Achilles Therapeutics PLC
Via GlobeNewswire
3 Stocks With 1,000% Upside Potential
If you're an investor comfortable with speculative bets, analysts are price targeting these stocks with 1000% upside. 
Via InvestorPlace
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
- New AI module delivers a "Target-to-T cell” approach for revolutionizing the identification and prioritization of targets for personalized antigen approaches - 
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company’s operations are not affected by the receipt of the Notice 
From Achilles Therapeutics PLC
Via GlobeNewswire
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
From Achilles Therapeutics PLC
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.